Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy [Phase 2]
A Phase 2 clinical trial evaluating durvalumab with local consolidative therapy for oligoprogressive and polyprogressive stage III non-small…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway [Phase 1]
A Phase 1 study evaluating MRTX0902 in solid tumors with KRAS MAPK pathway mutations has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for PF-07265028 as a single agent and in combination with sasanlimab in advanced/metastatic solid tumors has b…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease [Phase 2]
Phase 2 clinical trial update for treatment in patients with advanced non-small cell lung cancer and interstitial lung disease; the study is…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating ensartinib with carboplatin, pemetrexed, and bevacizumab for ALK-positive non-small cell lung cancer at Stage IIIC/…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
Recruitment is underway for a study to identify predictive biomarkers of pneumonitis risk in non-small cell lung cancer patients treated wit…
-
EMA approval · 2026-02-18EMA Authorised: Cejemly (sugemalimab) — Cstone Pharmaceuticals Ireland Limited
EMA has authorised Cejemly (sugemalimab) for non-small cell lung cancer.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer [Phase 3]
A Phase 3 pivotal study is planned to compare YL202 against Docetaxel in patients with EGFR-sensitive, non-squamous non-small cell lung canc…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer [Phase 2]
This Phase 2 study investigates high-low mixed-dose radiotherapy combined with chemo-immunotherapy induction for locally advanced non-small …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update details a biomarker-guided allogeneic CAR-NK cell therapy using single-target or dual-target constructs for advan…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy [Phase 2]
A Phase 2 clinical trial in advanced Non-Small Cell Lung Cancer is evaluating whether selecting patients by the fraction of ctDNA can guide …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab with or without chemotherapy in combination with additional treatments for advanced non-sm…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
Tasca Therapeutics is testing CP-383 in a Phase 1/2 trial for patients with advanced or metastatic solid tumors, including colorectal cancer…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer [Phase 2]
A multicenter, open-label Phase II study is evaluating cemiplimab plus chemotherapy in advanced squamous non-small cell lung cancer, selecte…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations [Phase 3]
A Phase 3 study of poziotinib in previously treated locally advanced or metastatic non-small cell lung cancer with HER2 exon 20 mutations ha…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
This clinical trial update describes a study evaluating brigatinib treatment information in Chinese participants with non-small cell lung ca…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC [NA]
This entry reports a real-world study evaluating pralsetinib in combination with Leucogen for RET fusion-positive non-small cell lung cancer…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression [Phase 2]
A Phase II, prospective, single-arm multicenter trial evaluating chidamide in combination with ivonescimab for advanced non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update reports a completed Phase 1/2 study of ALT-803 in combination with nivolumab for pretreatment, advanced or metast…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Single-Center, Prospective Phase II Clinical Study of Proton Beam Intensity-Modulated Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer [NA]
A single-center prospective Phase II study is evaluating proton beam intensity-modulated stereotactic radiotherapy for early-stage non-small…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases [Phase 2]
A Phase 2 clinical trial evaluating limertinib in combination with radiotherapy for EGFR-mutant non-small cell lung cancer with brain metast…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC [Phase 2]
Phase 2 study evaluating QL1706 plus chemotherapy and bevacizumab in PD-L1 ≥50% non-squamous non-small cell lung cancer; the trial is curren…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Phase Ib Study of HS-10504 Combined Therapy in NSCLC [Phase 1]
A Phase Ib trial of HS-10504 in combination therapy for non-small cell lung cancer is registered and not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) [Phase 3]
A Phase 3 trial comparing DZD9008 with platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer; the…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
Expanded access program for Zidesamtinib (NVL-520) in patients with advanced ROS1-positive solid tumors, including ROS1-positive non-small c…